Literature DB >> 19966939

Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA.

Longgui Wang, Xuanyi Zou, Aaron D Berger, Christian Twiss, Yi Peng, Yirong Li, Jason Chiu, Hongfeng Guo, Jaya Satagopan, Andrew Wilton, William Gerald, Ross Basch, Zhengxin Wang, Iman Osman, Peng Lee.   

Abstract

Histone deacetetylases (HDACs) are a group of corepressors of transcriptional activators and their levels of expression are potentially dysregulated in prostate cancer. Certain inhibitors of histone deacetylases show anti-tumor activity in prostate cancer cell lines. Here, we systemically studied the expression of HDACs in human prostate cancer and the suppression of prostate cancer growth and invasion by HDAC inhibitor SAHA. HDAC1-5 showed increased expression using a combination of DNA microarray, in-situ hybridization, and immunohistochemistry in benign and malignant human prostate tissue as well as RT-PCR and Western blot analysis on various PCa cell lines. Importantly, HDAC inhibitor SAHA suppressed, in particular, prostate cancer cell growth and invasion determined using cell proliferation and Matrigel invasion assays. The findings of this study show that the expression of HDACs and their associated corepressors are increased in prostate cancer in humans and HDAC inhibitor SAHA could serve as a potential therapeutic agent in prostate cancer in addition to anti-androgens.

Entities:  

Keywords:  Prostate cancer; androgen; corepressor; histone deacetylase; hormone receptor; in situ hybridization; microarray

Year:  2009        PMID: 19966939      PMCID: PMC2776287     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  34 in total

Review 1.  Nuclear receptor coregulators: cellular and molecular biology.

Authors:  N J McKenna; R B Lanz; B W O'Malley
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

2.  Histone deacetylase and DNA methyltransferase in human prostate cancer.

Authors:  S K Patra; A Patra; R Dahiya
Journal:  Biochem Biophys Res Commun       Date:  2001-09-28       Impact factor: 3.575

3.  Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.

Authors:  Yasunari Takada; Ann Gillenwater; Haruyo Ichikawa; Bharat B Aggarwal
Journal:  J Biol Chem       Date:  2005-12-23       Impact factor: 5.157

4.  Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase.

Authors:  Johnathan R Whetstine; Julian Ceron; Brendon Ladd; Pascale Dufourcq; Valerie Reinke; Yang Shi
Journal:  Mol Cell       Date:  2005-05-13       Impact factor: 17.970

Review 5.  Androgen receptor corepressors: an overview.

Authors:  Liang Wang; Cheng-Lung Hsu; Chawnshang Chang
Journal:  Prostate       Date:  2005-05-01       Impact factor: 4.104

6.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.

Authors:  Ping Zhu; Elke Martin; Jörg Mengwasser; Peter Schlag; Klaus-Peter Janssen; Martin Göttlicher
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

Review 7.  Histone deacetylase inhibitors: multifunctional anticancer agents.

Authors:  Tao Liu; Selena Kuljaca; Andrew Tee; Glenn M Marshall
Journal:  Cancer Treat Rev       Date:  2006-03-03       Impact factor: 12.111

Review 8.  Molecular biology of the androgen receptor.

Authors:  Edward P Gelmann
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

Review 9.  Emerging roles of MTA family members in human cancers.

Authors:  Rakesh Kumar; Rui-An Wang; Rozita Bagheri-Yarmand
Journal:  Semin Oncol       Date:  2003-10       Impact factor: 4.929

10.  Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate.

Authors:  K Halkidou; S Cook; H Y Leung; D E Neal; C N Robson
Journal:  Eur Urol       Date:  2004-03       Impact factor: 20.096

View more
  33 in total

1.  Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.

Authors:  Michael A Pereira; Blake M Warner; Thomas J Knobloch; Christopher M Weghorst; Ronald A Lubet; Vernon E Steele; Bruce C Casto
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

2.  A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Authors:  Kern Rei Chng; Cheng Wei Chang; Si Kee Tan; Chong Yang; Shu Zhen Hong; Noel Yan Wei Sng; Edwin Cheung
Journal:  EMBO J       Date:  2012-04-24       Impact factor: 11.598

3.  The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.

Authors:  Brian M Zeglis; NagaVaraKishore Pillarsetty; Vadim Divilov; Ronald A Blasberg; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

Review 4.  Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds.

Authors:  John T Pinto; Jeong-In Lee; Raghu Sinha; Melanie E MacEwan; Arthur J L Cooper
Journal:  Amino Acids       Date:  2010-04-10       Impact factor: 3.520

Review 5.  Histone deacetylases and mechanisms of regulation of gene expression.

Authors:  Hong Ping Chen; Yu Tina Zhao; Ting C Zhao
Journal:  Crit Rev Oncog       Date:  2015

6.  Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases.

Authors:  Vijay S Thakur; Karishma Gupta; Sanjay Gupta
Journal:  Carcinogenesis       Date:  2011-11-23       Impact factor: 4.944

7.  MicroRNA-188 inhibits proliferation migration and invasion of prostate carcinoma by targeting at MARCKS.

Authors:  Yao Zhang; Wen Zhang; Aiming Xu; Ye Tian; Chao Liang; Zengjun Wang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

Review 8.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

9.  Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer.

Authors:  Yifei Tang; Wenying Yan; Jiajia Chen; Cheng Luo; Antti Kaipia; Bairong Shen
Journal:  BMC Syst Biol       Date:  2013-10-16

10.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.